TENAFLY, N.J.--(BUSINESS WIRE)--SAFE-BioPharma Association, the non-profit coalition of biopharmaceutical companies that developed and manages the global SAFE-BioPharma® digital identity management and digital signature standards, today announced that Cidara Therapeutics, Inc. has joined the association. Cidara Therapeutics, Inc. (Nasdaq: CDTX) is a biotechnology company developing novel anti-infectives, including immunotherapies.
In use since 2005, the SAFE-BioPharma standard describes requirements for standardized identity trust for either authentication (the process that proves the user's identity to the computer system) or for digital signing (the strongest form of electronic signature in existence). Cidara Therapeutics is using the standard in combination with Adobe Acrobat to apply digital signatures to a variety of electronic documents.
"We welcome Cidara Therapeutics to the association's expanding body of member companies that utilize the SAFE-BioPharma standard to improve their digital operations, while enhancing security and regulatory compliance, " said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.
A recently introduced version of the standard creates a broader and more flexible ecosystem for recognition of authentication credentials.
Both sets of standards allow a single, trusted cyber identity credential to be recognized across their respective ecosystems.
The SAFE-BioPharma® standards for digital identity and digital signatures are used in life science and health care.
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Use of this trademark requires approval from SAFE-BioPharma Association.
Cidara is headquartered in San Diego, California.